Accéder au contenu
Merck

P9297

Paromomycin sulfate salt

≥98% (TLC)

Synonyme(s) :

Aminosidine sulfate

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C23H45N5O14 · xH2SO4
Numéro CAS:
1263-89-4
Poids moléculaire :
615.63 (free base basis)
NACRES:
NA.85
PubChem Substance ID:
24278662
UNSPSC Code:
51281663
Beilstein/REAXYS Number:
5715182

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Paromomycin sulfate salt, ≥98% (TLC)

InChI

1S/C23H45N5O14.CH4/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;/h5-23,29-36H,1-4,24-28H2;1H4/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1

SMILES string

O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O[C@@]2([H])[C@H](O[C@@]3([H])[C@H](O)[C@H](O[C@]4([H])[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O4)[C@@H](CO)O3)[C@@H](O)[C@H](N)C[C@@H]2N)[C@@H]1N.C

InChI key

OYJABWUHUYVDMJ-UDXJMMFXSA-N

assay

≥98% (TLC)

form

powder

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
parasites

mode of action

protein synthesis | interferes

Quality Level

200

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. It has in vitro and in vivo activity similar to neomycin. It is effective against Gram-negative bacteria, Gram-positive bacteria, some protozoan species, and limited antihelminth.
It is used to study bacterial protein synthesis at the level of 16S ribosomal RNA and 30S ribosome assembly. Paromomycin is used to study cytosine-cytosine (CC) mismatch-containing RNA molecules and is used to inhibit Cryptosporidium infection of a human enterocyte cell line.

Biochem/physiol Actions

Antimicrobial spectrum: Gram-negative and Gram-positive bacteria, some protozoan species, and limited antihelminth.
Mode of Action: Inhibits initiation and elongation during protein synthesis.
Paromomycin inhibits the initiation and elongation steps of protein synthesis by binding to 16S ribosomal RNA. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced and leads to cell death.

General description

Chemical structure: aminoglycoside

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Packaging

1g,5g,25g

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000508845
0000504479
0000435255
0000435255
0000370747

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Tony J Tavares et al.
RNA (New York, N.Y.), 15(5), 911-922 (2009-03-31)
The structure of a cytosine-cytosine (CC) mismatch-containing RNA molecule derived from a hairpin structure in the thymidylate synthase mRNA that binds the aminoglycoside paromomycin with high affinity was determined using nuclear magnetic resonance (NMR) spectroscopy. The cytosines in the mismatch
R J Marshall et al.
The Journal of infectious diseases, 165(4), 772-774 (1992-04-01)
Cryptosporidium parvum is a protozoan parasite that causes severe enteritis in patients with AIDS for which there is no effective therapy. Paromomycin is a nonabsorbable aminoglycoside that is effective in the treatment of other intestinal protozoa. The ability of paromomycin
Kazuki Saito et al.
Nucleic acids research, 43(9), 4591-4601 (2015-04-22)
In eukaryotes, the tRNA-mimicking polypeptide-chain release factor, eRF1, decodes stop codons on the ribosome in a complex with eRF3; this complex exhibits striking structural similarity to the tRNA-eEF1A-GTP complex. Although amino acid residues or motifs of eRF1 that are critical
Vasundhra Bhandari et al.
PLoS neglected tropical diseases, 6(5), e1657-e1657 (2012-05-26)
With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support
Sarah Hendrickx et al.
PLoS neglected tropical diseases, 6(5), e1664-e1664 (2012-06-06)
Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. Although no clinical resistance has yet been reported, proactive vigilance should be warranted. The present in vitro study compared the outcome and stability of experimental PMM-resistance induction
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique